OncoMatch/Clinical Trials/NCT03919552
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Is NCT03919552 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel,Carboplatin and Docetaxel,Cisplatin for cisplatin.
Treatment: Docetaxel,Carboplatin · Docetaxel,Cisplatin — The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage T3-4NX, TXN2-3 (8th American Joint Commission on Cancer edition)
Tumor staged as T3-4Nx/TxN2-3 (according to the 8th American Joint Commission on Cancer edition). No evidence of distant metastasis (M0).
Prior therapy
Cannot have received: radiotherapy
Exception: except for non-melanomatous skin cancers outside intended RT treatment volume
History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)
Cannot have received: chemotherapy
Prior chemotherapy
Cannot have received: surgery
Exception: except diagnostic
Prior surgery (except diagnostic) to primary tumor or nodes
Lab requirements
Blood counts
leucocyte count ≥4000/μL, hemoglobin ≥90g/L, platelet count ≥100000/μL
Kidney function
creatinine clearance ≥60 ml/min
Liver function
ALT, AST <1.5×ULN; ALP ≤2.5×ULN; bilirubin ≤ULN
Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL. Normal liver function test: ALT, AST <1.5×ULN; ALP ≤2.5×ULN, and bilirubin ≤ULN. Adequate renal function: creatinine clearance ≥60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify